SKShigenobu Kanba

Shigenobu Kanba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shigenobu Kanba has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression

    by Shigenobu Kanba, Mitsukuni Murasaki, Tsukasa Koyama, Masahiro Takeuchi, Yuriko Shimizu, Eri Arita, Kentaro Kuroishi, Shinya Kamei

    In an 8-week, randomized, placebo-controlled, double-blind study, an extended-release formulation of quetiapine, quetiapine XR, demonstrated efficacy and safety in Japanese patients with bipolar depression. Bipolar disorder is a chronic disease requiring continuous treatment. This was a long-term (52-week), open-label, non-controlled extension study to evaluate the long-term safety and efficacy of quetiapine XR in Japanese patients with bipolar depression who had previously completed the initial 8-week double-blind study. Efficacy was determined by the Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Depression Scale 17-item (HAM-D17), and Clinical Global Impressions-Bipolar scale (CGI-BP). Safety evaluations included analysis of adverse events, clinical laboratory measures, vital signs, Drug-induced Extrapyramidal Symptoms Scale, Young Mania Rating Scale, and the Columbia Suicide Severity Rating Scale. The mean (SD) MADRS total score decreased from 30.9 (6.9) at baseline to 16.1 (10.6) at week 8, and eventually to 9.1 (8.7) at week 52. The sustained efficacy of quetiapine XR treatment was also shown using HAM-D17 total scores, CGI-BP-Severity and Change evaluations. The most common adverse events were somnolence, nasopharyngitis, and thirst. Long-term treatment with quetiapine XR caused no substantial changes in the safety profiles, including clinical laboratory parameters, and no new safety concerns were identified. The efficacy of quetiapine XR was sustained long-term and no new safety concerns were identified in Japanese patients with bipolar depression. ClinicalTrials.gov Registration: NCT01725308. Date of registration; 12th November 2012 (retrospectively registered).


  • Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression

    by Mitsukuni Murasaki, Tsukasa Koyama, Shigenobu Kanba, Masahiro Takeuchi, Yuriko Shimizu, Eri Arita, Kentaro Kuroishi, Shinya Kamei

    The original version of this article contained a mistake in Table 5. Correct version is presented here.


  • Open Access

    Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression

    by Mitsukuni Murasaki, Tsukasa Koyama, Shigenobu Kanba, Masahiro Takeuchi, Yuriko Shimizu, Eri Arita, Kentaro Kuroishi, Masahiro Takeuchi, Shinya Kamei

    Rationale Quetiapine fumarate is an atypical antipsychotic indicated for various mental disorders, but it has not been studied in Japanese patients with bipolar depression. Objectives To evaluate the efficacy and safety of quetiapine XR (extended release) in Japanese patients with bipolar depression. Methods In this multi-center, randomized, double-blind, placebo-controlled, fixed-dose study of 431 Japanese adults with bipolar I or II disorder, efficacy was determined by analyzing the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary end points included MADRS response and remission rates, Hamilton Depression Scale 17-Item (HAM-D17), and Clinical Global Impressions-Bipolar (CGI-BP) scale scores. Safety was determined by monitoring adverse events and clinical assessments. Results This study revealed a statistically significantly greater decrease in MADRS total score after 8 weeks of quetiapine XR 300 mg/day monotherapy compared with placebo (− 12.6 vs. − 10.1; p = 0.034). There were also improvements in MADRS response (44.1 vs. 35.6%) and remission (38.0 vs. 26.6%) rates as well as in HAM-D17 and CGI-BP scale scores compared with placebo. In the subgroup analysis of patients with bipolar I or II disorder, the adjusted mean changes in MADRS total score compared to placebo were − 2.3 and − 2.1, respectively. Adverse events occurred in 149 patients (83.2%) receiving quetiapine XR 300 mg/day and in 81 patients (45.8%) receiving placebo. The most common adverse events were somnolence and thirst, which is consistent with the previously reported safety profile. Conclusions Once-daily monotherapy with quetiapine XR is an effective and well-tolerated treatment for bipolar depression in Japanese patients.


  • Open Access

    A pilot study exploring the association of morphological changes with 5-HTTLPR polymorphism in OCD patients

    by Shinichi Honda, Tomohiro Nakao, Hiroshi Mitsuyasu, Kayo Okada, Leo Gotoh, Mayumi Tomita, Hirokuni Sanematsu, Keitaro Murayama, Keisuke Ikari, Masumi Kuwano, et al.

    Clinical and pharmacological studies of obsessive-compulsive disorder (OCD) have suggested that the serotonergic systems are involved in the pathogenesis, while structural imaging studies have found some neuroanatomical abnormalities in OCD patients. In the etiopathogenesis of OCD, few studies have performed concurrent assessment of genetic and neuroanatomical variables. We carried out a two-way ANOVA between a variable number of tandem repeat polymorphisms (5-HTTLPR) in the serotonin transporter gene and gray matter (GM) volumes in 40 OCD patients and 40 healthy controls (HCs). We found that relative to the HCs, the OCD patients showed significant decreased GM volume in the right hippocampus, and increased GM volume in the left precentral gyrus. 5-HTTLPR polymorphism in OCD patients had a statistical tendency of stronger effects on the right frontal pole than those in HCs. Our results showed that the neuroanatomical changes of specific GM regions could be endophenotypes of 5-HTTLPR polymorphism in OCD.


  • Current viewpoints on DSM‐5 in Japan

    by Toshihide Kuroki, Makoto Ishitobi, Yoko Kamio, Genichi Sugihara, Toshiya Murai, Keisuke Motomura, Kazuyoshi Ogasawara, Hiroyuki Kimura, Branko Aleksic, Norio Ozaki, et al.

    The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) was published in 2013, and its official Japanese version was published in 2014. The Japanese Government uses classifications from the 10th revision of the I nternational C lassification of D iseases (ICD‐10) to categorize disorders and determine treatment fees. However, since the publication of the DSM‐III, the use of the DSM system has become prevalent in research and educational settings in Japan. In addition to traditional psychiatry, both the ICD and the DSM are taught by many Japanese medical schools, and virtually all clinical research and trials refer to the DSM to define targeted disorders. Amid the current backdrop in which the reputation of the DSM‐5 is being established, the editorial board of P sychiatry and C linical N eurosciences has asked Japanese experts across 12 specialties to examine the structure of the DSM‐5, including the following categories: Neurodevelopmental Disorders, Schizophrenia Spectrum Disorders, Major Depression, Bipolar Disorders, Obsessive–Compulsive Disorders, Somatic Symptom Disorder, Eating Disorders, Substance‐Related and Addictive Disorders, Gender Dysphoria, and Neurocognitive Disorders. Although opinions were only obtained from these selected experts, we believe that we have succeeded, to a certain extent, in presenting views that are representative of each specialty.


  • Acknowledgments

    by Shigenobu Kanba, Tadafumi Kato

  • Hikikomori Assessment Interview

    by Alan R. Teo, Michael D. Fetters, Kyle Stufflebam, Masaru Tateno, Yatan Balhara, Tae Young Choi, Shigenobu Kanba, Carol A. Mathews, Takahiro A. Kato

  • Conquering depression

    by Tadafumi Kato, Shigenobu Kanba


  • Bipolar treatment efficacy – Authors' reply

    by Tomofumi Miura, Toshi A Furukawa, Andrea Cipriani, Keisuke Motomura, Hiroshi Mitsuyasu, Shiro Tanaka, Stefan Leucht, Satomi Shimano-Katsuki, Georgia Salanti, Hisashi Noma, et al.